Back to top

vaccines: Archive

Andrew Rocco

Why Novavax is Gaining Ground in COVID-19 Vaccine Race

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry.

SNYPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change

Zacks Equity Research

MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.

SNYPositive Net Change GSKPositive Net Change MRKPositive Net Change MRNAPositive Net Change

Zacks Equity Research

Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.

GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change PCVXNegative Net Change

Zacks Equity Research

Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine

The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.

SNYPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change

Zacks Equity Research

Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs

PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.

PFEPositive Net Change LLYNegative Net Change FULCNo Net Change BVSNegative Net Change

Zacks Equity Research

AstraZeneca (AZN) Denies Rumors About UK Facility Relocation

Per third-party reports, AstraZeneca (AZN) has refuted rumors about considering a change in the relocation of a vaccine manufacturing plant from the U.K. to the United States.

AZNPositive Net Change ARCTNegative Net Change FULCNo Net Change BVSNegative Net Change